Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Summary
The purpose of this phase I/II study is to evaluate the safety and efficacy of 9-ING-41, a potent GSK-B inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers, including pancreatic cancer.
General Information
NCT#: NCT03678883
Study ID: 1801
Trial Phase: Phase I/II
Trial Sponsor: Actuate Therapeutics Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Irinotecan, Carboplatin, Paclitaxel, Doxorubicin, 9-ING-41, lomustine